The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study.
Autor: | Madeira Gerardo A; Pulmonology, Hospital Professor Doutor Fernando Fonseca, Lisboa, PRT., da Silva Alves C; Pulmonology, Hospital Professor Doutor Fernando Fonseca, Lisboa, PRT., Gomes M; Allergy and Immunology, Hospital de Santa Maria, Unidade Multidisciplinar de Asma Grave, Lisboa, PRT., Pardal C; Pulmonology, Hospital Professor Doutor Fernando Fonseca, Lisboa, PRT., Sokolova A; Pulmonology, Hospital Professor Doutor Fernando Fonseca, Lisboa, PRT., Liberato H; Pulmonology, Hospital Professor Doutor Fernando Fonseca, Lisboa, PRT., Mendes A; Allergy and Immunology, Hospital de Santa Maria, Unidade Multidisciplinar de Asma Grave, Lisboa, PRT., Tonin FS; Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa (ESTeSL) Instituto Politécnico de Lisboa (IPL), Lisbon, PRT., Duarte-Ramos F; Pharmacy, University of Lisbon, Lisbon, PRT., Lopes C; Pulmonology, Hospital de Santa Maria, Unidade Multidisciplinar de Asma Grave, Lisboa, PRT. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cureus [Cureus] 2024 Jan 17; Vol. 16 (1), pp. e52452. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2024). |
DOI: | 10.7759/cureus.52452 |
Abstrakt: | Introduction: Add-on biological monoclonal antibodies such as benralizumab (anti-IL-5Ra) are recommended by international guidelines to reduce exacerbations in severe eosinophilic asthma (SEA). However, few studies have assessed the impact of these therapies on lung function-related outcomes. Our goal was to evaluate the effectiveness of benralizumab on lung function, including lung volumes and airway resistance, in SEA patients in Portugal. Methods: This was a real-world, observational, prospective, multicentric study including adult patients diagnosed with SEA (January-June 2023). Spirometry and plethysmography were performed at baseline (T0) and after six months of treatment (T6) with benralizumab to assess: total lung capacity (TLC), residual volume (RV), forced expiratory volume in one second (FEV Results: Overall, 30 SEA patients were evaluated, mostly women (n=18, 60.0%), with atopy (n=22, 73.3%), a mean age of 58.4 years (SD 11.7), and assisted by pulmonology (n=19, 63.3%) or immunology-allergology (n=11, 36.7%) services. Mean eosinophilia at baseline was 1103.57 cells/mcL (SD 604.88; minimum-maximum 460-2400); after the use of benralizumab, the count dropped to zero. After six months of treatment, a significant increase (p<0.0001) in FVC (15.3%), FEV Conclusions: A notable eosinophil depletion with add-on benralizumab led to significant improvements in SEA patients' respiratory function (static lung volumes and airway resistance) in real-world settings after six months. The significant deflating effect of benralizumab on patients' hyperinflated lungs led to enhanced expiratory flow (increased FEV Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Madeira Gerardo et al.) |
Databáze: | MEDLINE |
Externí odkaz: |